Drug Database · Clinicians

Bicalutamide

Brands (20) Bicalude, Casodex, Riki…Show all

Androgen Receptor Inhibitor (Androgen Receptor Antagonists) US FDA class
Anti-androgen; Antineoplastic agent PH FDA category

Rx · Prescription drug24 PH productsPNF-listedVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID dfee4fe7-8478-4a3e-925d-00be3cd0ab67, version date February 27, 2026 (CASODEX · ANI Pharmaceuticals, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate.
  • CASODEX 150 mg daily is not approved for use alone or with other treatments.
US FDA label
Full indications and usage US FDA label

1. INDICATIONS AND USAGE CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. CASODEX 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies (14.2)].

  • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. (1)
  • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1)

Contraindications

4. CONTRAINDICATIONS CASODEX is contraindicated in: • Hypersensitivity CASODEX is contraindicated in any patient who has shown a hypersensitivity reaction to the drug or any of the tablet’s components. Hypersensitivity reactions including angioneurotic edema and urticaria have been reported. • Women CASODEX has no indication for women, and should not be used in this population. • Pregnancy CASODEX can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)]. • Hypersensitivity (4) • Women (4) • Pregnancy (4, 8.1)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

2. DOSAGE AND ADMINISTRATION The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening). (2) 2.1. Recommended Dose and Schedule The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food.

It is recommended that CASODEX be taken at the same time each day. Treatment with CASODEX should be started at the same time as treatment with an LHRH analog. If a dose of CASODEX is missed, take the next dose at the scheduled time. Do not take the missed dose and do not double the next dose. 2.2. Dosage Adjustment in Renal Impairment No dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)]. 2.3.

Dosage Adjustment in Hepatic Impairment No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration)

Renal Impairment No dosage adjustment is necessary for patients with renal impairment [see Use in Specific Populations (8.7)]. 2.3. Dosage Adjustment in Hepatic Impairment No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. In patients with severe liver impairment (n=4), although there was a 76% increase in the half-life (5.9 and 10.4 days for normal and impaired patients, respectively) of the active enantiomer of bicalutamide no dosage adjustment is necessary [see Use in Specific Populations (8.6)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4. Pediatric Use The safety and effectiveness of CASODEX in pediatric patients have not been established. CASODEX (bicalutamide) orodispersible tablet was studied in combination with ARIMIDEX (anastrozole) orodispersible tablet in an open-label, non-comparative, multi-center study that assessed the efficacy and safety of this combination regimen over 12 months in the treatment of gonadotropin-independent precocious puberty in boys with familial male-limited precocious puberty, also known as testotoxicosis.

Patients were enrolled in the study if they had a baseline age ≥2 years and a diagnosis of testotoxicosis based on clinical features of progressive precocious puberty, symmetrical testicular enlargement, advanced bone age, pubertal levels of serum testosterone, prepubertal pattern of gonadotropin secretion following a GnRH stimulation test, and absence of other clinical and biochemical causes of testosterone excess. Thirteen out of the 14 patients enrolled completed 12 months of combination treatment (one patient was lost to follow-up).

If central precocious puberty (CPP) developed an LHRH analog was to be added. Four patients were diagnosed with CPP during the 12-month study and received LHRH analog treatment and 2 additional patients were diagnosed at the end of the 12 months and received treatment subsequently. Mean ± SD characteristics at baseline were as follows: chronological age: 3.9±1.9 years; bone age 8.8±2.5; bone age/chronological age ratio: 2.06±0.51; growth rate (cm/yr): 10.81±4.22; growth rate standard deviation score (SDS): 0.41±1.36.

The starting CASODEX dose was 12.5 mg. CASODEX was titrated in each patient until steady-state R-bicalutamide (the active isomer of bicalutamide) trough plasma concentration reached 5-15 mcg/mL, which is the range of therapeutic concentrations achieved in adults with prostate cancer following the administration of the currently approved CASODEX dose of 50 mg.

The starting daily dose of anastrozole was 0.5 mg. Anastrozole was independently titrated in each patient until it reached at steady-state a serum estradiol concentration of <10 pmol/L (2.7 pg/mL). The following ascending doses were used for CASODEX: 12.5 mg, 25 mg, 50 mg, and 100 mg. For anastrozole there were two ascending doses: 0.5 mg and 1 mg.

At the end of the titration phase, 1 patient was on 12.5 mg CASODEX, 8 patients were on 50 mg CASODEX, and 4 patients were on 100 mg CASODEX; 10 patients were on 0.5 mg anastrozole and 3 patients were on 1 mg anastrozole. In the majority of patients, steady-state trough concentrations of R-bicalutamide appeared to be attained by Day 21 with once daily dosing.

Steady-state trough plasma anastrozole concentrations appeared to be attained by Day 8. The primary efficacy analysis of the study was to assess the change in growth rate after 12 months of treatment, relative to the growth rate during the ≥6 months prior to entering the study. Pre-study growth rates were obtained retrospectively.

There was no statistical evidence that the growth rate was reduced during treatment. During CASODEX/ARIMIDEX treatment the mean growth rate (cm/yr) decreased by 1.6 cm/year, 95% CI (-4.7 to 1.5) p=0.28; the mean growth rate SDS decreased by 0.1 SD, 95% CI (-1.2 to 1.0) p=0.88. Table 2 shows descriptive data for growth rates for the overall population and for subgroups defined by history of previous treatment for testotoxicosis with ketoconazole, spironolactone, anastrozole or other aromatase inhibitors.

Table 2. Growth Rates Analysis population Pre-study Mean Change from pre-study to 12 months % patients with growth reduction 1 Mean Median (Min, Max) Growth rate (cm/yr) All treated (n=13) 10.8 -1.6 -2.8 (-7.4, 8.4) 9/13 (69%) PT 2 (n=6) 10.3 -0.2 -2.6 3 (-7.2, 8.4) 4/6 (67%) NPT 4 (n=7) 11.2 -2.8 -2.8 (-7.4, 1.1) 5/7 (71%) Growth rate (SD units) All treated (n=13) 0.4 -0.1 -0.4 (-2.7, 3.5) 9/13 (69%) PT 2 (n=6) -0.1 +0.7 -0.2 3 (-1.6, 3.5) 4/6 (67%) NPT 4 (n=7) 0.8 -0.7 -0.4 (-2.7, 0.5) 5/7 (71%) 1.

Change compared to pre study growth rate. 2. PT = Previous treatment for testotoxicosis with ketoconazole, spironolactone, anastrozole or other aromatase inhibitors. 3. Median calculated as midpoint of 3 rd and 4 th ranked observations. 4. NPT = no previous treatment for testotoxicosis with ketoconazole, spironolactone, anastrozole, or other aromatase inhibitors.

Total testosterone concentrations increased by a mean of 5 mmol/L over the 12 months of treatment from a baseline mean of 10 mmol/L. Estradiol concentrations were at or below the level of quantification (9.81 pmol/L) for 11 of 12 patients after 12 months of treatment. Six of the 12 patients started treatment at an estradiol concentration below the level of quantification.

There were no deaths, serious adverse events, or discontinuations due to adverse events during the study. Of the 14 patients exposed to study treatment, 13 (92.9%) experienced at least one adverse event. The most frequently reported (>3 patients) adverse events were gynecomastia (7/14, 50%), central precocious puberty (6/14, 43%), vomiting (5/14, 36%), headache (3/14, 21%), pyrexia (3/14, 21%), and upper respiratory tract infection (3/14, 21%).

Adverse reactions considered possibly related to bicalutamide by investigators included gynecomastia (6/14, 43%), central precocious puberty (2/14, 14%), breast tenderness (2/14, 14%), breast pain (1/14, 7%), asthenia (1/14, 7%), increased alanine aminotransferase [ALT] (1/14, 7%), increased aspartate aminotransferase [AST] (1/14, 7%), and musculoskeletal chest pain (1/14, 7%). Headache was the only adverse reaction considered possibly related to anastrozole by investigators.

For the patient who developed elevated ALT and AST, the elevation was <3X ULN, and returned to normal without stopping treatment; there was no concomitant elevation in total bilirubin.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5. Geriatric Use In two studies in patients given 50 or 150 mg daily, no significant relationship between age and steady-state levels of total bicalutamide or the active R-enantiomer has been shown.

Dosage forms

Philippines

  • Film-coated tablet: 50 mg, 150 mg
  • Enteric-coated tablet: 50 mg
  • Tablet: 50 mg, 150 mg

Registered products in the Philippines

24 products registered with the Food and Drug Administration (FDA) Philippines list Bicalutamide as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products24
Philippine FDA-registered products for Bicalutamide
Package insert
AndroxenBicalutamide
50 mg Film-coated TabletPVC/PVDC/Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Kwang Dong Pharmaceutical Co., Ltd.Republic of Korea
JC 28 Pharmaceutical Products WholesalingImporter: JLT Pharma Inc.
DRP-17159-01
Sep 9, 2030
Bica-AceBicalutamide
50 mg Film-Coated TabletAlu/Amber PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Admac LifesciencesIndia
Genace Pharma DistributorImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-16310-01
Feb 4, 2030
BicadexBicalutamide
50 mg Film-Coated TabletBlister Pack x 10's (Box of 30's)
RxVAT-exempt
Salutas Pharma GmbHGermany
Importer: Sandoz Philippines Corporation
DRP-2585
Nov 19, 2029
BicaludeBicalutamide
50 mg Enteric-Coated TabletPVC/PVDC/Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Kwang Dong Pharmaceutical Co., Ltd.Korea
JLT Pharma Inc.
DR-XY49486
Sep 9, 2030
BicaludeBicalutamide
50 mg Enteric-Coated TabletPVC / PVDC / Alu Blister Pack x 14's (Box of 28’s)
RxVAT-exempt
Kwang Dong Pharmaceutical Co., Ltd.Republic of Korea
Importer: JLT Pharma Inc.
DRP-17159
Sep 9, 2030
Bicalut-50Bicalutamide
50 mg Film-Coated TabletAlu/Amber PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Admac LifesciencesIndia
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-16310
Feb 4, 2030
BicamBicalutamide
50 mg Film-Coated Tablet
RxVAT-exempt
Hetero Labs Limited
Multi Product Line Pharma, Inc.Importer: Camber Pharmaceuticals, Inc.
DRP-7765-01
Dec 4, 2026
Bicamid 50Bicalutamide
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 28's, 30's and 40's)
RxVAT-exempt
Celogen Generics Pvt. Ltd.India
Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-5397-01
Dec 18, 2027
BicaprosBicalutamide
50 mg Film-coated Tablet
RxVAT-exempt
Laboratorios Richmond S.A.C.I.F
UNILAB, Inc.
DR-XY40573
Jan 27, 2027
Bicatero 150Bicalutamide
150 mg Film-Coated Tablet
RxVAT-exempt
Hetero Labs Limited
Camber Pharmaceuticals, Inc.
DRP-7766
Dec 4, 2026
Bicatero 50Bicalutamide
50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's); Alu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Hetero Labs LimitedIndia
Camber Pharmaceuticals, Inc.
DRP-7765
Dec 4, 2031
CalubiaBicalutamide
50 mg Film-Coated TabletBlister Pack x 10's (Box of 30's)
RxVAT-exempt
SALUTAS PHARMA GMBHGermany
THE CATHAY DRUG CO., INC.Importer: SANDOZ PHILIPPINES CORPORATION
DRP-2585-01
Nov 19, 2029
CaluminBicalutamide
50 mg Film-Coated TabletPVC/PVDC - Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Oncolife Corporation
DRP-7488
Feb 10, 2031
CasodexBicalutamide
150 mg TabletAlu/PVC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Corden Pharma GmbHGermany
Importer: AstraZeneca Pharmaceuticals (Phils.), Inc.Trader: AstraZeneca UK Limited
DR-XY27244
Feb 3, 2029
CasodexBicalutamide
50 mg TabletAlu/PVC Blister Pack x 14's Box of 28's
RxVAT-exempt
Corden Pharma GmbHGermany
Importer: AstraZeneca Pharmaceuticals (Phils.), Inc.Trader: AstraZeneca UK Limited
DRP-10062
Apr 2, 2029
Celobic 50Bicalutamide
50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 40's); Alu/Clear PVC Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Celogen Generics Private Ltd.India
Pharmastar Int'l Trading Corp.
DRP-5397
Dec 18, 2027
CosalonBicalutamide
50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's); Alu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
I.E. Medica, Inc.
DRP-4622
Aug 23, 2028
LutaprostBicalutamide
50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Globela Pharma Private Limited.India
AMB HK Enterprises Inc.
DRP-15215
May 29, 2029
NoneBicalutamide
50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Medethix, Inc.Importer: I.E. Medica, Inc.
DRP-4622-01
Aug 23, 2028
ProcalBicalutamide
50 mg Film-coated TabletPVC/PVDC-Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Accord Healthcare Limited - Philippine Branch OfficeImporter: Oncolife Corporation
DRP-7488-01
Feb 10, 2031
ProsmideBicalutamide
50 mg Film-Coated TabletWhite Opaque PVC/PE/PVDC/Al Blister Pack x 7's (Box of 28's)
RxVAT-exempt
Synthon Hispania, SLSpain
Macropharma CorporationTrader: Synthon BV
DR-XY45386
May 23, 2031
ProtikideBicalutamide
50 mg Film-Coated TabletPVC / PVDC / Alu Blister Pack x 14's (Box of 28's)
RxVAT-exempt
Kwang Dong Pharmaceutical Co., Ltd.Republic of Korea
Ellebasy Medicale Group Inc.Importer: JLT Pharma Inc.
DRP-17159-02
Sep 9, 2030
RikiBicalutamide
50 mg Film-Coated TabletAlu / Amber PVC Blister Pack x 10's (Box of 30’s)
RxVAT-exempt
Admac LifesciencesIndia
Kaufmann Pharma Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-16310-02
Feb 4, 2030
RikiBicalutamide
50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Celon Laboratories Private LimitedIndia
Kaufmann Pharma Inc.Importer: I.E. Medica, Inc.
DRP-4622-02
Aug 23, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3. DOSAGE FORMS AND STRENGTHS CASODEX ® (bicalutamide) 50 mg tablets for oral administration. 50 mg tablets (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label

5. WARNINGS AND PRECAUTIONS

  • Severe hepatic injury and fatal hepatic failure have been observed. Monitor serum transaminase levels prior to starting treatment with CASODEX, at regular intervals for the first four months of treatment and periodically thereafter, and for symptoms or signs suggestive of hepatic dysfunction. Use CASODEX with caution in patients with hepatic impairment. (5.1)
  • Hemorrhage with Concomitant Use of Coumarin Anticoagulant. Closely monitor the Prothrombin Time (PT) and International Normalized Ratio (INR), and adjust the anticoagulant dose as needed. (5.2)
  • Gynecomastia and breast pain have been reported during treatment with CASODEX 150 mg when used as a single agent. (5.3)
  • CASODEX is used in combination with an LHRH agonist. LHRH agonists have been shown to cause a reduction in glucose tolerance in males. Consideration should be given to monitoring blood glucose in patients receiving CASODEX in combination with LHRH agonists. (5.4)
  • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate for clinical progression if PSA increases. (5.5) 5.1. Hepatitis Cases of death or hospitalization due to severe liver injury (hepatic failure) have been reported postmarketing in association with the use of CASODEX. Hepatotoxicity in these reports generally occurred within the first three to four months of treatment. Hepatitis or marked increases in liver enzymes leading to drug discontinuation occurred in approximately 1% of CASODEX patients in controlled clinical trials. Serum transaminase levels should be measured prior to starting treatment with CASODEX, at regular intervals for the first four months of treatment, and periodically thereafter. If clinical symptoms or signs suggestive of liver dysfunction occur (e.g., nausea, vomiting, abdominal pain, fatigue, anorexia, “flu-like” symptoms, dark urine, jaundice, or right upper quadrant tenderness), the serum transaminases, in particular the serum ALT, should be measured immediately. If at any time a patient has jaundice, or their ALT rises above two times the upper limit of normal, CASODEX should be immediately discontinued with close follow-up of liver function. 5.2. Hemorrhage with Concomitant Use of Coumarin Anticoagulant In the postmarketing setting, there have been reports of excessive prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) days to weeks after the introduction of CASODEX in patients who were previously stable on coumarin anticoagulants. Some patients had serious bleeding including intracranial, retroperitoneal, and gastrointestinal requiring blood transfusion and/or administration of vitamin K. Closely monitor the PT/INR, and adjust the anticoagulant dose as needed [see Drug Interactions (7) and Adverse Reactions (6.2)]. 5.3. Gynecomastia and Breast Pain In clinical trials with CASODEX 150 mg as a single agent for prostate cancer, gynecomastia and breast pain have been reported in up to 38% and 39% of patients, respectively. 5.4. Glucose Tolerance A reduction in glucose tolerance has been observed in males receiving LHRH agonists. This may manifest as diabetes or loss of glycemic control in those with pre-existing diabetes. Consideration should therefore be given to monitoring blood glucose in patients receiving CASODEX in combination with LHRH agonists. 5.5. Laboratory Tests Regular assessments of serum Prostate Specific Antigen (PSA) may be helpful in monitoring the patient’s response. If PSA levels rise during CASODEX therapy, the patient should be evaluated for clinical progression. For patients who have objective progression of disease together with an elevated PSA, a treatment-free period of antiandrogen, while continuing the LHRH analog, may be considered.

Drug interactions

Drug interactions (US label) US FDA label

7. DRUG INTERACTIONS Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes. In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity.

Clinical studies have shown that with co-administration of CASODEX, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5-fold (for C max) and 1.9-fold (for AUC). Hence, caution should be exercised when CASODEX is co-administered with CYP 3A4 substrates. In vitro protein binding studies have shown that bicalutamide can displace coumarin anticoagulants from binding sites.

PT/INR should be closely monitored in patients concomitantly receiving coumarin anticoagulants and CASODEX. Adjustment of the anticoagulant dose may be necessary [see Warnings and Precautions (5.2) and Adverse Reactions (6.2)].

  • R-bicalutamide is an inhibitor of CYP 3A4; therefore, caution should be used when CASODEX is co-administered with CYP 3A4 substrates. (7)
  • PT/INR should be closely monitored in patients already receiving coumarin anticoagulants who are started on CASODEX. (7)
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity.

Clinical studies have shown that with co-administration of CASODEX, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5-fold (for C max ) and 1.9-fold (for AUC).

Hence, caution should be exercised when CASODEX is co-administered with CYP 3A4 substrates.

Adjustment of the anticoagulant dose may be necessary [see Warnings and Precautions (5.2) and Adverse Reactions (6.2) ]. • R-bicalutamide is an inhibitor of CYP 3A4; therefore, caution should be used when CASODEX is co-administered with CYP 3A4 substrates.

Adverse reactions

Adverse reactions (US label) US FDA label

6. ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse reactions that occurred in more than 10% of patients receiving CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral edema, dyspnea, diarrhea, hematuria, nocturia, and anemia.

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1. Clinical Trials Experience In patients with advanced prostate cancer treated with CASODEX in combination with an LHRH analog, the most frequent adverse reaction was hot flashes (53%).

In the multi-center, double-blind, controlled clinical trial comparing CASODEX 50 mg once daily with flutamide 250 mg three times a day, each in combination with an LHRH analog, the following adverse reactions with an incidence of 5% or greater, regardless of causality, have been reported. Table 1. Incidence of Adverse Reactions (≥ 5% in Either Treatment Group) Regardless of Causality Body System Adverse Reaction Treatment Group Number of Patients (%) CASODEX Plus LHRH Analog (n=401) Flutamide Plus LHRH Analog (n=407) Body as a Whole Pain (General) 142 (35) 127 (31) Back Pain 102 (25) 105 (26) Asthenia 89 (22) 87 (21) Pelvic Pain 85 (21) 70 (17) Infection 71 (18) 57 (14) Abdominal Pain 46 (11) 46 (11) Chest Pain 34 (8) 34 (8) Headache 29 (7) 27 (7) Flu Syndrome 28 (7) 30 (7) Cardiovascular Hot Flashes 211 (53) 217 (53) Hypertension 34 (8) 29 (7) Digestive Constipation 87 (22) 69 (17) Nausea 62 (15) 58 (14) Diarrhea 49 (12) 107 (26) Increased Liver Enzyme Test 30 (7) 46 (11) Dyspepsia 30 (7) 23 (6) Flatulence 26 (6) 22 (5) Anorexia 25 (6) 29 (7) Vomiting 24 (6) 32 (8) Hemic and Lymphatic Anemia 45 (11) 53 (13) Metabolic and Nutritional Peripheral Edema 53 (13) 42 (10) Weight Loss 30 (7) 39 (10) Hyperglycemia 26 (6) 27 (7) Alkaline Phosphatase Increased 22 (5) 24 (6) Weight Gain 22 (5) 18 (4) Musculoskeletal Bone Pain 37 (9) 43 (11) Myasthenia 27 (7) 19 (5) Arthritis 21 (5) 29 (7) Pathological Fracture 17 (4) 32 (8) Nervous System Dizziness 41 (10) 35 (9) Paresthesia 31 (8) 40 (10) Insomnia 27 (7) 39 (10) Anxiety 20 (5) 9 (2) Depression 16 (4) 33 (8) Respiratory System Dyspnea 51 (13) 32 (8) Cough Increased 33 (8) 24 (6) Pharyngitis 32 (8) 23 (6) Bronchitis 24 (6) 22 (3) Pneumonia 18 (4) 19 (5) Rhinitis 15 (4) 22 (5) Skin and Appendages Rash 35 (9) 30 (7) Sweating 25 (6) 20 (5) Urogenital Nocturia 49 (12) 55 (14) Hematuria 48 (12) 26 (6) Urinary Tract Infection 35 (9) 36 (9) Gynecomastia 36 (9) 30 (7) Impotence 27 (7) 35 (9) Breast Pain 23 (6) 15 (4) Urinary Frequency 23 (6) 29 (7) Urinary Retention 20 (5) 14 (3) Urinary Impaired 19 (5) 15 (4) Urinary Incontinence 15 (4) 32 (8) Other adverse reactions (greater than or equal to 2%, but less than 5%) reported in the CASODEX-LHRH analog treatment group are listed below by body system and are in order of decreasing frequency within each body system regardless of causality.

Body as a Whole: Neoplasm; Neck Pain; Fever; Chills; Sepsis; Hernia; Cyst Cardiovascular: Angina Pectoris; Congestive Heart Failure; Myocardial Infarct; Heart Arrest; Coronary Artery Disorder; Syncope Digestive: Melena; Rectal Hemorrhage; Dry Mouth; Dysphagia; Gastrointestinal Disorder; Periodontal Abscess; Gastrointestinal Carcinoma Metabolic and Nutritional: Edema; BUN Increased; Creatinine Increased; Dehydration; Gout; Hypercholesteremia Musculoskeletal: Myalgia; Leg Cramps Nervous: Hypertonia; Confusion; Somnolence; Libido Decreased; Neuropathy; Nervousness Respiratory: Lung Disorder; Asthma; Epistaxis; Sinusitis Skin and Appendages: Dry Skin; Alopecia; Pruritus; Herpes Zoster; Skin Carcinoma; Skin Disorder Special Senses: Cataract Specified Urogenital: Dysuria; Urinary Urgency; Hydronephrosis; Urinary Tract Disorder Abnormal Laboratory Test Values: Laboratory abnormalities including: elevated AST, ALT, bilirubin, BUN, and creatinine; and decreased hemoglobin and white cell count, have been reported in both CASODEX-LHRH analog treated and flutamide-LHRH analog treated patients. 6.2. Postmarketing Experience The following adverse reactions have been identified during post-approval use of CASODEX.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Respiratory disorders: Interstitial lung disease (some fatal) including interstitial pneumonitis and pulmonary fibrosis, most often at doses greater than 50 mg.

Hemorrhage: Increased PT/INR due to interaction between coumarin anticoagulants and CASODEX. Serious bleeding reported. [see Warnings and Precautions (5.2)] Skin and subcutaneous tissue disorders: Photosensitivity

Adverse reaction frequency tables (US label) US FDA label
Table 1. Incidence of Adverse Reactions (≥ 5% in Either Treatment Group) Regardless of Causality
Body System Adverse ReactionTreatment Group Number of Patients (%)
CASODEX Plus LHRH Analog (n=401)Flutamide Plus LHRH Analog (n=407)
Body as a Whole
Pain (General)142 (35)127 (31)
Back Pain102 (25)105 (26)
Asthenia89 (22)87 (21)
Pelvic Pain85 (21)70 (17)
Infection71 (18)57 (14)
Abdominal Pain46 (11)46 (11)
Chest Pain34 (8)34 (8)
Headache29 (7)27 (7)
Flu Syndrome28 (7)30 (7)
Cardiovascular
Hot Flashes211 (53)217 (53)
Hypertension34 (8)29 (7)
Digestive
Constipation87 (22)69 (17)
Nausea62 (15)58 (14)
Diarrhea49 (12)107 (26)
Increased Liver Enzyme Test30 (7)46 (11)
Dyspepsia30 (7)23 (6)
Flatulence26 (6)22 (5)
Anorexia25 (6)29 (7)
Vomiting24 (6)32 (8)
Hemic and Lymphatic
Anemia45 (11)53 (13)
Metabolic and Nutritional
Peripheral Edema53 (13)42 (10)
Weight Loss30 (7)39 (10)
Hyperglycemia26 (6)27 (7)
Alkaline Phosphatase Increased22 (5)24 (6)
Weight Gain22 (5)18 (4)
Musculoskeletal
Bone Pain37 (9)43 (11)
Myasthenia27 (7)19 (5)
Arthritis21 (5)29 (7)
Pathological Fracture17 (4)32 (8)
Nervous System
Dizziness41 (10)35 (9)
Paresthesia31 (8)40 (10)
Insomnia27 (7)39 (10)
Anxiety20 (5)9 (2)
Depression16 (4)33 (8)
Respiratory System
Dyspnea51 (13)32 (8)
Cough Increased33 (8)24 (6)
Pharyngitis32 (8)23 (6)
Bronchitis24 (6)22 (3)
Pneumonia18 (4)19 (5)
Rhinitis15 (4)22 (5)
Skin and Appendages
Rash35 (9)30 (7)
Sweating25 (6)20 (5)
Urogenital
Nocturia49 (12)55 (14)
Hematuria48 (12)26 (6)
Urinary Tract Infection35 (9)36 (9)
Gynecomastia36 (9)30 (7)
Impotence27 (7)35 (9)
Breast Pain23 (6)15 (4)
Urinary Frequency23 (6)29 (7)
Urinary Retention20 (5)14 (3)
Urinary Impaired19 (5)15 (4)
Urinary Incontinence15 (4)32 (8)

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1. Pregnancy Risk Summary CASODEX is contraindicated for use in pregnant women because it can cause fetal harm. CASODEX is not indicated for use in females. There are no human data on the use of CASODEX in pregnant women. In animal reproduction studies, oral administration of bicalutamide to pregnant rats during organogenesis caused abnormal development of reproductive organs in male fetuses at exposures approximately 0.7 to 2 times the human exposure at the recommended dose (see Data).

Data Animal Data In an embryo-fetal development study in pregnant rats dosed during the period of organogenesis from gestation days 6-15, male fetuses had reduced anogenital distance at doses of 10 mg/kg/day and above (approximately 0.7 to 2 times the human exposure at the recommended dose). In a pre- and post-natal development study, female rats were dosed from gestation day 7-16 and allowed to litter and rear their offspring to weaning.

Male offspring of rats receiving doses of 10 mg/kg/day (approximately 0.7 times the human exposure at the recommended dose) and above, were observed to have reduced anogenital distance. In a peri- and post-natal development study, female rats were dosed from gestation day 16 to lactation day 22 and allowed to litter and rear their offspring to weaning.

Survival and weights of offspring during lactation were reduced for litters from maternal rats receiving doses of 250 mg/kg/day (approximately 2 times the human exposure at the recommended dose). Male offspring of rats receiving doses of 10 mg/kg/day (approximately 0.7 times the human exposure at the recommended dose) and above, were observed to have reduced anogenital distance, smaller secondary sex organs, cryptorchidism and hypospadias resulting in an inability to mate and impregnate their female partners.

Female offspring of rats receiving doses of 10 mg/kg/day (approximately 0.7 times the human exposure at the recommended dose) and above had reduced pregnancy rates.

Mechanism of action

12.1. Mechanism of Action CASODEX is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen.

When CASODEX is combined with LHRH analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. However, in clinical trials with CASODEX as a single agent for prostate cancer, rises in serum testosterone and estradiol have been noted. In a subset of patients who have been treated with CASODEX and an LHRH agonist, and who discontinue CASODEX therapy due to progressive advanced prostate cancer, a reduction in Prostate Specific Antigen (PSA) and/or clinical improvement (antiandrogen withdrawal phenomenon) may be observed.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Both the parent and metabolite glucuronides are eliminated in the urine and feces.

Pharmacokinetics of CASODEX Active Enantiomer Parameter Mean Standard Deviation Normal Males (n=30) Apparent Oral Clearance (L/hr) 0.320 0.103 Single Dose Peak Concentration (mcg/mL) 0.768 0.178 Single Dose Time to Peak Concentration (hours) 31.3 14.6 Half-life (days) 5.8 2.29 Patients with Prostate Cancer (n=40) C ss (mcg/mL) 8.939 3.504

Pharmacokinetics (US label) US FDA label

12.3. Pharmacokinetics Absorption Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. Co-administration of bicalutamide with food has no clinically significant effect on rate or extent of absorption. Distribution Bicalutamide is highly protein-bound (96%) [see Drug Interactions (7)].

Metabolism/Elimination Bicalutamide undergoes stereospecific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation. Both the parent and metabolite glucuronides are eliminated in the urine and feces.

The S-enantiomer is rapidly cleared relative to the R-enantiomer, with the R-enantiomer accounting for about 99% of total steady-state plasma levels. Pharmacokinetics of the active enantiomer of CASODEX in normal males and patients with prostate cancer are presented in Table 3. Table 3. Pharmacokinetics of CASODEX Active Enantiomer Parameter Mean Standard Deviation Normal Males (n=30) Apparent Oral Clearance (L/hr) 0.320 0.103 Single Dose Peak Concentration (mcg/mL) 0.768 0.178 Single Dose Time to Peak Concentration (hours) 31.3 14.6 Half-life (days) 5.8 2.29 Patients with Prostate Cancer (n=40) C ss (mcg/mL) 8.939 3.504

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Bicalutamide 50 mg film-coated tablet₱30.00per tabletDPRI reference price

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Bicalutamide
PNF listingOral: 50 mg and 150 mg tablet/ film coated tablet
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. CASODEX · ANI Pharmaceuticals, Inc. [US FDA-approved label, version 6, February 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfee4fe7-8478-4a3e-925d-00be3cd0ab67
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .